RHT Health Trust (“RHT” or the “Trust”) is constituted as a business trust under the Business Trusts Act (Chapter 31A) (“BTA”) and is externally managed by RHT Health Trust Manager Pte. Ltd. (“RHT TM” or the “Trustee-Manager”). The Trustee-Manager recognises the importance of upholding high corporate governance standards which serves to safeguard the interests of Unitholders and contribute to the success of RHT. Under the BTA, the Trustee-Manager must act in the best interests of Unitholders as a whole.
The Trustee-Manager uses the Code of Corporate Governance 2012 (“CG Code 2012”) as its benchmark for best corporate governance practices and has established policies and practices with the CG Code 2012 in mind. The Trustee-Manager has also incorporated specific provisions under the Business Trusts Regulations (“BTR”) in its corporate governance framework.
The Trustee-Manager also proactively tracks and voluntarily complies with the provisions and requirements under the Code on Collective Investment Schemes issued by the Monetary Authority of Singapore (“CIS Code”). This includes the Property Funds Appendix in Appendix 6 of the CIS Code, as well as the various laws and regulations which are applicable to Capital Market Services Licence (“CMS Licence”) holders.
In this Corporate Governance Report (“CG Report”), we have described the main corporate governance policies and practices which the Trustee-Manager has established, with reference to the CG Code 2012. Any deviations from the CG Code 2012 are explained in this CG Report.
Principle 1: Every company should be headed by an effective Board to lead and control the company. The Board is collectively responsible for the long-term success of the company. The Board works with Management to achieve this objective and Management remains accountable to the Board.
The Board of RHT TM (the “Board”) plays a pivotal role in providing entrepreneurial leadership, setting the strategic direction for RHT, overseeing that necessary financial and human resources are in place, reviewing management performance, and guiding the management of RHT TM in achieving efficient management of the Trust. Along with monitoring the achievement of these goals, the Board is also responsible for making sure that the management has an internal and risk management controls framework in place. This helps RHT to achieve its goals while taking into account the interest of its Unitholders.
A total of three Committees have been set up with their own terms of reference to assist the Board in the discharge of its duties. These three Committees are:
The ARMC assists the Board by reviewing significant financial reporting issues and considers the report of the external auditor. The ARMC also oversees the risk management framework and policies of RHT and has oversight of the internal audit function. The NC supports the Board by evaluating and providing recommendations on the composition of the Board in terms of size, independence and skill requirements. The RC will in turn evaluate and recommend an appropriate remuneration framework to the Board. The terms of reference for each Committee, as well as the members of each Committee (together with their role in the Committee and whether they are independent or executive) are described in the Appendix to this CG Report.
The Board of Directors meet at least four times a year to review and approve the financial results of RHT as well as to receive key reports from both the external professionals such as the internal auditors, and senior management. The Board also reviews and approves, amongst others, RHT’s strategic direction, its annual budget, capital structuring, risk reports and key policies. As and when warranted by circumstances, Board meetings are also held outside of the quarterly meetings to discuss the strategies, policies or key activities of RHT such as acquisitions and disposals. Under the Constitution of the Trustee-Manager, Board meetings are permitted to be held via telephone conference or by means of similar communication equipment whereby all persons participating in the meeting are able to hear and/or see each other.
The names of our current Directors and details of their membership on Board Committees, number of Board and Committee meetings held for FY2018, as well as their attendance at these meetings are disclosed in the table below:
|Name||Board||Audit and Risk Management Committee||Nominating Committee||Remuneration Committee|
|No. of meetings held||No. of meetings attended||No. of meetings held||No. of meetings attended||No. of meetings held||No. of meetings attended||No. of meetings held||No. of meetings attended|
|Mr Ravi Mehrotra1||8||41||-||-||1||1||-||-|
|Mr Gurpreet Singh Dhillon||8||8||-||-||-||-||-||-|
|Mr Pawanpreet Singh||8||8||-||-||-||-||-||-|
|Dr Yogendra Nath Mathur||8||8||6||6||1||1||-||-|
|Mr Sydney Michael Hwang||8||5||-||-||1||1||2||2|
|Mr Peter Joseph Seymour Rowe||8||8||6||6||-||-||2||2|
|Mr Eng Meng Leong||8||8||6||6||-||-||2||2|
|Mr Vivek Mehra2||8||42||-||-||1||-3||-||-|
The Trustee-Manager has formalised the following matters which are specifically reserved for decision and approval by the Board:
Apart from the matters reserved specifically for the Board’s decision and approval, the Board has delegated the supervision of the day to day operations as well as the decision making over certain operational matters to the management of RHT TM in order to facilitate operational efficiency.
Newly appointed Directors to the Board of RHT TM are issued an appointment letter which spells out their duties and obligations as a Director, whereby they are required to objectively discharge their duties and responsibilities at all times as fiduciaries in the interests of RHT and RHT TM. A briefing is also conducted by senior management to provide an overview of the business of RHT as well as the key policies and Board processes. Material documents pertaining to RHT are also made available to the new Directors. First time Directors who are appointed to the Board will also be provided external training by professional providers, such as the Singapore Institute of Directors, on what they need to know as a Director of a listed company in Singapore. The Independent Directors seek to conduct a site visit to India every year where the assets of RHT are located. During the site visit, the Independent Directors also meet with the India based senior management of RHT and external professionals such as internal auditors and external auditors.
The Trustee-Manager monitors new laws, regulations and rules that are implemented, for implications on RHT and RHT TM. Where relevant, Directors are updated about the changes to existing or new rules and regulations. There have been briefings conducted during Board meetings whereby either senior management or external professionals update the Directors on new developments or where the Board deems that expert advice is required in order to formulate key decisions. In FY2018, management briefed the Board on the implementation of the Goods and Services Tax (“GST”) in India, proposed changes to the Code of Corporate Governance and Quarterly Reporting Framework, as well as the launch of the Governance Index for Trusts (“GIFT”). KPMG Services Pte. Ltd. (“KPMG”) also briefed the Board on the new Singapore Exchange Limited (“SGX”) rule which requires all listed companies in Singapore to prepare an annual Sustainability Report. Where required, the Trustee-Manager also arranges and funds the training for Directors so that they are kept abreast of any regulatory changes. Our Directors also received copies of the recent guidebooks purchased by RHT TM which were released in Singapore for the ARMC, NC and RC.
The Board has engaged KPMG to assist the Trustee-Manager with developing RHT’s inaugural Sustainability Report, which can be found on pages 45 to 64 of the Annual Report. The Board has ultimate responsibility and oversight for the Sustainability Report. Management has established a Sustainability Working Committee and a Sustainability Steering Committee, for reporting of sustainability issues to the Board on at least a quarterly basis.
Principle 2: There should be a strong and independent element on the Board, which is able to exercise objective judgement on corporate affairs independently, in particular, from Management and 10% shareholders. No individual or small group of individuals should be allowed to dominate the Board’s decision making.
There are seven Directors on the Board of RHT TM, of which a majority or five of the Directors, including the Chairman of the Board, are independent and Non-executive Directors. The remaining two Directors are Executive and Non-independent Directors.
The BTR provides that:
The NC determines the independence of each Director annually, or as and when required. The NC has carried out its assessment for FY2018, and with the concurrence of the Board, considered and found Mr Vivek Mehra, Mr Sydney Michael Hwang, Mr Eng Meng Leong, Dr Yogendra Nath Mathur and Mr Peter Joseph Seymour Rowe to be independent from:
Mr Ravi Mehrotra, our former Executive Chairman, Mr Gurpreet Singh Dhillon, our Chief Executive Officer (“CEO”) and Mr Pawanpreet Singh, our Chief Financial Officer (“CFO”) are not considered to be independent under the CG Code 2012 and/or the BTR Section 3 and 4.
The Board does not currently comprise of any Director who has served on the Board for more than nine years from the date of his first appointment. Refer to page 83 of the CG Report for details on the appointment dates of the Board of Directors.
The current Board comprises of seven Directors with extensive experience in various fields ranging from legal, investments, tax and accounting to healthcare. Although none of the current Board of Directors are female, RHT TM does not discriminate against gender diversity within the Board. However, RHT TM does not actively set targets on the proportion of male to female Board members. Instead, Board of Directors are appointed based on best fit and qualification for the role.
The NC has evaluated the size and composition of the Board and is of the view that the size of the Board is appropriate in relation to the scale of RHT’s operations, and that the Board possesses the requisite experience for managing a healthcare infrastructure related trust such as RHT.
1 Independent from management and business relationships with the Trustee-Manager as defined under Section 3 of the BTR.
2 Independent from substantial shareholder of the Trustee-Manager as defined under Regulation 4 of the BTR.
Although all Directors have an equal responsibility in overseeing the performance of RHT, Non-executive Directors in particular are responsible for ensuring that conflicts of interest, if any, are appropriately managed and ensure that decisions are taken in the interest of the Trust. Non-executive Directors also participate in annual strategy discussions, review the performance of management in achieving agreed goals and objectives and monitor the reporting of performance. The Non-executive Directors have met at least once during FY2018 without management present.
Principle 3: There should be a clear division of responsibilities between the leadership of the Board and the executives responsible for managing the company’s business. No one individual should represent a concentration of power.
The positions of the Chairman of the Board and the CEO are held by two separate persons for accountability and effective segregation of duties. The Board of RHT TM is led by our Non-executive Chairman, Mr Vivek Mehra, while Mr Gurpreet Singh Dhillon is our CEO. Mr Vivek Mehra and Mr Gurpreet Singh Dhillon are not immediate family members. The division of responsibilities between the Chairman and CEO are clearly established, set out in writing and approved by the Board.
As Chairman of the Board, Mr Mehra leads the Board in carrying its role effectively and engages the Directors in discussing and debating on issues while working towards important decisions. He sets the agenda for the Board meetings and makes sure that adequate time is available for discussion of all agenda items. The Chairman also oversees that Directors receive complete, adequate and timely information. Board papers are disseminated to the Board approximately five business days before each Board meeting. The Chairman is responsible for promoting effective communication with Unitholders. Refer to Principle 15 on page 76 to 77 of the CG Report for details on measures taken by the Trustee-Manager to promote effective communication with Unitholders.
The Chairman also encourages constructive relations within the Board and between the Board and management. As our Nonexecutive Directors have diverse backgrounds and experience, the Board and management benefit from their views on matters being tabled before the Board. Mr Mehra facilitates the effective contribution of Non-executive Directors and strives for high standards of corporate governance to be maintained within RHT.
The CEO is responsible for managing the daily operations of the Trust and the Trustee-Manager in accordance with the business plans and strategies which have been set out by the Board.
There is clear segregation of roles within the Board. The ARMC, NC and RC each have their own terms of reference and responsibilities. Each of the three Committees are headed by a different Independent Director, and no individual Director on the Board has a considerable concentration of power. The NC has also obtained approval from the Board to have the Chairman of each committee reviewed once every three years. This is also recommended under Clause 1.10 of the Board Risk Committee Guide (“BRCG”) issued on 31 March 2016. Clause 1.10 recommends reviewing the tenure and renewal of Board Committee members so as to introduce new perspectives and allow for transfer of accumulated knowledge.
Dr Yogendra Nath Mathur is our lead Independent Director. He serves as a conduit between Unitholders and the Board, or between the Independent Directors and the Board, whenever there are concerns from either party.
The Independent Directors have private sessions and feedback sessions with the Chairman without the presence of management
Principle 4: There should be a formal and transparent process for the appointment and re-appointment of Directors to the Board.
The Board approved the establishment of an NC comprising of a majority of Independent Directors, including the lead Independent Director. The role of the NC under its terms of reference as approved by the Board includes making recommendations on:
During the search for a new Director, the Board shortlists suitable candidates based on criteria which takes into consideration the roles and expertise that is required of the new Director and the needs of the Board. The potential candidates may originate from various sources such as recommendations from management and Directors, the Singapore Institute of Directors or utilising external search consultants. The shortlisted candidates are presented to the NC for consideration, with the final candidate as selected by the NC presented to the Board for approval.
Under the appointment letters signed with the Independent Directors that are appointed to the Board of RHT TM, the Directors are required to put themselves up for re-nomination and re-election once every three years. The re-nominated Directors are evaluated by the NC, approved by the Board, presented to Unitholders during the Annual General Meeting (“AGM”) and approved by Stellant (the substantial shareholder of RHT TM).
The NC is also tasked with ascertaining if each Director, having multiple directorships, is able and has been adequately carrying out his duties as a Director. This review is performed by the NC annually and takes into consideration the Director’s number of listed company Board representations and other principal commitments. The NC is of the view that the number of directorships held by a Director does not determine the performance of the Director. A Director’s performance is assessed based on a number of factors including their time commitment towards Board meetings and discussions, their ability to draw on their experience to contribute to the strategy and decision making required of the Board. As such, the NC proposed with the concurrence of the Board, that there will be no fixed limit on the number of directorships which a Director may hold but rather to assess the performance of each Director as a whole.
RHT TM does not currently permit the appointment of alternate Directors and has not adopted any polices and guidelines for the appointment of alternate Directors.
Information on the academic and professional qualifications of the Directors can be found on pages 21 to 22 of the Annual Report. The shareholdings of the Directors in RHT Group and its related corporations, Board Committees served on, date of first appointment, directorships and chairmanships both present and past held over the preceding three years in other listed companies, and other principal commitments are disclosed on pages 83, 88, 90 and 92 of the Annual Report.
Principle 5: There should be a formal annual assessment of the effectiveness of the Board as a whole and its Board Committees and the contribution by each Director to the effectiveness of the Board.
A formal assessment is conducted annually to determine the effectiveness of the Board, the Board Committees and on each Director. The assessment is conducted using an evaluation form which is constantly updated for relevance. The Board is of the opinion that the current evaluation form is relevant and covers the necessary aspects of measuring the performance of the Board. The evaluation form seeks feedback from each Director on a confidential basis, on their views relating to:
For the annual assessment conducted in respect of the financial year ended 31 March 2018 (“FY2018”), the Company Secretary was responsible for sending the evaluation form to the Directors and collating the responses received. The results of the evaluation survey were then presented to the NC for its assessment and recommendation. In formulating the feedback form, attention was given to make sure that feedback was sought from the Directors on the core areas, whilst also enabling each Director to freely express their opinions on other matters in a confidential manner. The results of the evaluation, and the NC’s recommendations, were presented to the Board for their concurrence.
Principle 6: In order to fulfil their responsibilities, Directors should be provided with complete, adequate and timely information prior to Board meetings and on an on-going basis so as to enable them to make informal decisions to discharge their duties and responsibilities.
The calendar for Board and Committee meetings are arranged one year in advance to allow for better planning. Management provides the Board with monthly reports and/or calls, in addition to Board papers on matters which are being tabled during the Committee or Board meetings. Board papers are to be sent to the Board approximately five business days before the meeting takes place. Directors are also entitled to request for separate and independent access to management, the Company Secretary or external professionals. The Chairman of the ARMC meets separately with management as well as the internal and external auditors on a regular basis. These meetings take place on a quarterly basis with management and the internal auditors, and on a half yearly basis with the external auditors. As stipulated in the Director’s appointment letter, they are also entitled to seek independent professional advice relating to their roles and responsibilities as a Director of RHT TM, at RHT TM’s expense.
Management provides the Board with a call and/or report each month on the operating environment and financials of RHT. Matters such as the financial results, the report from the independent auditors, management’s internal risk assessment report as well as business and operational updates for the quarter are presented for the Board’s review during the quarterly Board meetings. In FY2018, management presented RHT’s strategy in the event of the Proposed Disposal and vice versa, to the Board for review and approval. Management also provided the Board with regular updates on the outstanding amounts due from Fortis as well as RHT’s cash flow requirements to continue operations. On an on-going basis, where there are material variances against the forecasted and actual financial figures, explanations would be provided.
The Company Secretary attends all Board and Board Committee meetings and is responsible for keeping accurate minutes on the proceedings. Their advice on matters relating to corporate governance may also be sought during these meetings. The Head of Compliance in RHT TM works together with the Company Secretary to facilitate good and timely information flow to the Board of Directors. Where there should be any proposed change to the Company Secretary, Board approval will be obtained.
Principle 7: There should be a formal and transparent procedure for developing policy on executive remuneration and for fixing remuneration packages of individual Directors. No Director should be involved in fixing his own remuneration.
Principle 8: The level and structure of remuneration should be aligned with the long term interest and risk policies of the company, and should be appropriate to attract, retain and motivate (a) the Directors to provide good stewardship of the company, and (b) key management personnel to successfully manage the company. However, companies should avoid paying more than is necessary for this purpose.
Principle 9: Every company should provide clear disclosure of its remuneration policies, level and mix of remuneration, and the procedure for setting remuneration, in the company’s Annual Report. It should provide disclosure in relation to its remuneration policies to enable investors to understand the link between remuneration paid to Directors and key personnel, and performance.
The Board approved the establishment of the RC with its own terms of reference. The members of the RC and the terms of reference of the RC are set out in the Appendix of this CG Report. The RC comprises of wholly independent Non-executive Directors who are responsible for reviewing the remuneration policy and framework of the Directors and the key management.
During the RC meeting held in February 2018, the RC reviewed the compensation structure for the Directors, as well as the compensation structure and package for key management of RHT TM. Under RHT TM’s compensation structure for its Directors, Executive Directors are not paid Director fees while Non-executive Directors are paid a fixed base fee as well as a variable fee for every additional role taken on by each Director. This serves to compensate the Directors according to the amount of responsibility, time and effort required for the role. In general, the Chairman of the Board and Board Committees are paid higher variable fees compared to members of the Committees. The remuneration framework for the Non-executive Directors is shown in the following table:
|Type of Director||Base Fee||Variable Fee|
|Non-Executive Director||Base Fee per annum.||Chairman||Member of Committee|
|50% of BF as Chairman of Board/ARMC||12.5% of Base Fee|
|25% of Base Fee as Chairman of RC or NC|
Non-executive Director fees are benchmarked against the market and industry levels such that the fees are sufficient to motivate and attract Directors, without being too generous to potentially compromise the independence of the Directors. The remuneration that is paid to the Directors of RHT TM are determined and paid from RHT TM (in its personal capacity) as approved by its shareholder, Stellant, and not out of RHT Trust property. Director fees paid to each of the following Non-executive Directors for FY2018 did not exceed S$250,000:
A review of the remuneration framework and the amounts paid to key management of RHT and RHT TM is conducted once a year. In FY2018, the remuneration plan was also introduced to place a greater emphasis on staff retention, in view of the ongoing Proposed Disposal. The Trustee-Manager has in place a performance based remuneration framework for its key management. There are currently no short-term and long-term incentive schemes in place. At present, the key management of RHT TM, including the CEO, are paid a fixed yearly salary with a performance related bonus that is linked to the performance of RHT TM. The performance of RHT TM is in turn linked to the performance of RHT. The main regular source of revenue earned by RHT TM is from the fees paid by RHT to RHT TM. The fees payable by RHT to RHT TM are based on (i) the value of the assets under management at RHT and (ii) the amount of Distributable Income generated at RHT. A greater growth in the value of RHT’s assets and the amount of Distributable Income available for Unitholders of RHT results in higher revenue for RHT TM. This serves to align management’s interests with that of the Trust.
The Trustee-Manager has also elected for the variable bonus to constitute a higher proportion of the total salary payable to key employees, in order to strengthen the link between the individual’s performance and their remuneration.
Expert advice is sought from an appointed remuneration consultant, Aon Hewitt, in order to assist the RC in their assessment on the appropriate compensation level for key management. A report is commissioned yearly to provide information on the remuneration paid by comparable peers in the industry. Aon Hewitt is an independent third party with no existing relationships with RHT and RHT TM. The Trustee-Manager does not engage any remuneration consultant with regard to the remuneration of its Directors.
Similar to the Directors, key management and employees of RHT TM are paid by the Trustee-Manager and not out of RHT’s Trust property.
None of the Directors or employees of RHT TM are paid in the form of shares or interests in the Trustee-Manager’s controlling shareholder or its related entities. There is currently no share incentive or employee share option scheme in place for management. There is also no scheme to encourage Non-executive Directors to hold shares in RHT.
The following table shows the remuneration in bands of S$250,000, of the former Executive Chairman, CEO, CFO as well as key management of the Trustee-Manager. The key management of the Trustee-Manager is determined based on the importance of their roles in the Trustee-Manager.
|Executive Directors||Remuneration Band||Fixed Salary||Bonus|
|Ravi Mehrotra1||S$0- 250,0002||100%||Nil|
|Gurpreet Singh Dhillon||S$ 750,000–1,000,000||66%||34%|
|Pawanpreet Singh||S$ 500,001–750,000||53%||47%|
1Mr Ravi Mehrotra resigned as Executive Director on 30 September 2017 and ceased to be the Executive Chairman of the Board and member of the NC on the same day.
2For the period 1 April 2017 to 30 September 2017.
|Key Management||Remuneration Band||Fixed Salary||Bonus|
|Tan Suan Hui||S$ 250,000–500,000||53%||47%|
Dr Ramnik Ahuja who is employed as Vice President of Research and Strategy, is the spouse of Mr Pawanpreet Singh, the CFO and Executive Director of RHT TM. Her annual remuneration fell within the band of S$50,000-100,000 in FY2018. Other than Dr Ramnik Ahuja, there are no other employees who are immediate family members of any Director or the CEO.
The Trustee-Manager is of the view that the disclosure of the specific remuneration of individual management personnel and key employees may lead to retention or recruitment difficulties in light of the relatively small number of trusts currently operating in Singapore. As compared to the number of listed companies in Singapore, listed trusts are relatively fewer in number and competition for talent in the trusts space may increase the risk of losing or retaining staff if such information were to be disclosed. For the same reasons, the Board has decided not to disclose the total aggregate remuneration of the Directors and key management personnel. However, their remuneration have been disclosed in bands, such that the minimum and maximum range is apparent. Furthermore, the remuneration paid to the management of RHT TM is from RHT TM, and not out RHT’s Trust property. The fees paid by RHT to RHT TM are disclosed on page 78 of this CG report.
The CG Code 2012 encourages the disclosure of the top five key management personnel (who are not Directors or the CEO) on a named basis in bands of S$250,000 as well as the aggregate remuneration paid to key management personnel. Due to the small size of the team at the Trustee-Manager, we have chosen to only disclose the remuneration of key personnel who has the authority and responsibility to assist the CEO in the strategic activities of the Trustee-Manager.
Currently, none of the Directors or key management has a contract with RHT TM that contain provisions on termination, retirement and post-employment benefits. There are also no contractual provisions to allow RHT TM to reclaim incentive components of remuneration from Executive Directors and key management personnel in exceptional circumstances of misstatement of financial results, or of misconduct resulting in financial loss to RHT.
Principle 10: The Board should present a balanced and understandable assessment of the company’s performance, position and prospects.
The Board is committed towards providing Unitholders of RHT with a balanced and understandable assessment of RHT’s performance, position and prospects. The financial results of RHT and any other material price sensitive information are disseminated via SGXNET, published on RHT’s website and also presented during investor meetings and quarterly conference calls with investors.
As mentioned under Principle 6 on Access to Information, the Board is provided with a monthly report which summarises the key financial performance of RHT against forecasted figures, as well as the business environment and pertinent operations of RHT. Where there are material variances from month to month, reasons for the variances are provided to the Board. The Board has also approved an internal Compliance Manual which compiles the relevant rules and regulations applicable to both RHT and RHT TM. This Compliance Manual serves to assist management in meeting the regulatory requirements.
Principle 12: The Board should establish an Audit Committee with written terms of reference which clearly set out its authority and duties.
The members of the ARMC of RHT TM are appointed from among the Directors of the Board and comprise of three Non-executive Independent Directors. They are:
Both Mr Peter Joseph Seymour Rowe and Mr Eng Meng Leong have appropriate qualifications to carry out their responsibilities and have relevant accounting and related financial management expertise and experience. Mr Rowe has over 40 years of experience in the financial services industry, particularly in the areas of funds management and compliance. He has been the Chairman and Audit Committee member of other real estate management related companies in Australia. Mr Eng is currently a member of the Institute of Certified Public Accountants of Singapore and is an accredited Tax Advisor of the Singapore Institute of Accredited Tax Professionals. He has over 25 years of experience in the fields of taxation in Singapore and internationally. Dr Mathur, a qualified doctor, has experience and expertise in the healthcare sector. He spent a large portion of his career with the United Nations Children’s Fund (“UNIFEF”), where he held key positions and memberships in several government bodies.
The background and qualifications of the ARMC members are set out on pages 21 and 22 of the Annual Report. The terms of reference of the ARMC are set out in the Appendix on pages 84 to 86 of this CG Report. The ARMC is given the authority to investigate any matter within its terms of reference, whenever it deems necessary. Where required, the ARMC is given full access to and cooperation by management, full discretion to invite any Director or Executive Officer to attend ARMC meetings, and reasonable resources to enable it to discharge its duties effectively.
The ARMC met six times in FY2018. During the year, the ARMC reviewed the quarterly and full year results of FY2018, including the adequacy of disclosures as well as the key changes in accounting policies applied. Management is kept abreast of changes in the accounting standards by both the external auditors and other sources. Every year, management reviews the changes in the accounting standards applicable to RHT and briefs the ARMC and Board about these changes.
On a quarterly basis, the ARMC also reviews the reports from the internal auditors with respect to their internal audit findings, as well as the report from the Internal Risk Committee of RHT TM on changes in key risks and policies affecting RHT. Management also provides the ARMC with quarterly reports on the actions taken to resolve previous internal audit findings. In addition, management prepares a liquidity report on RHT for the ARMC’s information and review. Key policies are reviewed by management on a regular basis to ensure that they are up to date and approved by the ARMC before it is presented to the Board.
All Interested Party Transactions (“IPT”) are tabled during the ARMC meeting. This is in accordance with our IPT policy, which sets out the procedure whereby such transactions are identified, reported and recorded in the IPT register. The terms of the transactions, including information to support that the transactions are conducted on normal commercial terms, are also recorded in the IPT register.
Details of the IPT entered into during the course of the current financial year ending 31 March 2018 between the RHT Group and interested persons (including Fortis, Religare Enterprises Limited and their respective subsidiaries and associates) which fall under the Listing Manual of the SGX-ST are set out below:
|No.||Interested Person||Nature of Transaction||Value of Transaction (S$)(1)||Percentage of NTA (2)|
|1||RWL Healthworld Limited3||Revenue share from
|2||SRL Diagnostics Limited||Revenue share from pathology
|3||Fortis Health Management Ltd||Intercompany borrowing||64,242||0.01%|
|3||RHT Health Trust Manager Pte. Ltd.||Bridging loan from
RHT Health Trust
(1)Values are converted at the end of each month as per the prevailing exchange rate at that month end.
(2) Based on the latest audited net tangible assets of RHT as of 31 March 2018 of S$623,105,000.
(3)RWL Healthworld Limited (“RWL”) is no longer a related party of Fortis Healthcare Limited and is no longer considered an interested person with effect from 1 March 2018 in view that the owners of RWL are no longer substantial shareholders of Fortis Healthcare Limited.
The transactions with RWL Healthworld Limited and SRL Diagnostics Limited involve the leasing out of space at various RHT Clinical Establishments to the aforementioned companies which are owned by Fortis Healthcare Limited and RHC Holding Private Limited respectively. The transactions with Fortis Health Management Ltd and RHT Health Trust Manager Pte. Ltd. relate to one-off borrowings3.
The ARMC also reviews the audit plans submitted by the internal and external auditor respectively for the forthcoming year. In FY2018, both the external and internal auditors met at least once during the year with the ARMC respectively without the presence of management. In the same financial year, the Chairman of the ARMC also met separately with the internal auditors every quarter and separately with the external auditor twice. It is also the practice of the ARMC Chairman to meet with the CFO of the Trustee- Manager prior to the quarterly ARMC meetings to review the financial reports.
The role of the ARMC includes reviewing the independence of the external auditors. For FY2018, the ARMC noted that S$152,000 was paid to the external auditors as audit fees and S$39,000 was paid for non-audit services. A discussion was held with the external auditors in relation to the type of non-audit services provided, and the ARMC was satisfied with the independence of the external auditors. No ARMC member is a former Partner or Director with the external audit firm. There are also no business or family relationships between the external auditors and management.
The Trustee-Manager has complied with Rule 712 and 715 of the SGX-ST Listing Manual. All of RHT’s foreign incorporated subsidiaries are audited by Deloitte Haskins & Sells LLP (“DHS”). The ARMC has assessed DHS and the Audit Partner’s track record and capabilities in carrying out work for similar companies in India. They have also discussed with DHS, the manner in which the audit is proposed to be carried out. The ARMC is of the view that DHS is a suitable audit firm to meet the RHT Group’s audit obligations.
RHT TM has established a Whistleblowing Policy to provide a channel for whistleblowers to report any actual or suspected wrongdoings, as well as to provide assurance that the whistleblower will be protected from reprisals or victimisation for whistleblowing. The Whistleblowing Policy is approved and overseen by the ARMC, and it provides an opportunity for employees and the public to raise concerns to the Head of Compliance of RHT TM and/or the Chairman of the ARMC. Investigations will commence upon the receipt of a whistleblowing report and follow up actions would be taken if necessary.
Principle 13: The company should establish an effective internal audit function that is adequately resourced and independent of the activities it audits.
The Trustee-Manager is committed to having an internal audit function at all times. KPMG has been appointed to perform the internal audit function for RHT. KPMG is guided by the Standards for the Professional Practice of Internal Auditing set by The Institute of Internal Auditors and the engagement team is staffed with personnel who possess the relevant qualifications and experience.
The selection and appointment of the internal audit firm for RHT was determined by the ARMC, and the internal audit plan for each financial year is approved by the ARMC. The scope of the internal audit is intended to cover key aspects of RHT and RHT TM’s internal controls in the areas of finance, operations, compliance and information technology. During the course of their work, the internal auditors are given full access to any documents, records or personnel, and they report directly to the ARMC Chairman.
As mentioned under the section “Audit Committee”, the Chairman of the ARMC meets the internal auditors every quarter. These meetings take place without the presence of management to allow the discussions to be as open and candid as possible. The ARMC has reviewed the internal audit plan for FY2018, the resources allocated to carrying out the plan, as well as the work done by the internal auditors over FY2018, and they are satisfied with the adequacy and effectiveness of the current internal auditor.
3The loan from RHT to RHT TM was a bridging loan while RHT TM was awaiting funds to be disbursed while refinancing a facility. The loan was repaid when the funds were received from the new facility and interest was accrued to RHT for the loan at market rate.
Principle 11: The Board is responsible for the governance of risk. The Board should ensure that Management maintains a sound system of risk management and internal controls to safeguard shareholders’ interests and company’s assets, and should determine the nature and extent of the significant risks which the Board is willing to take in achieving its strategic objectives.
Having an effective and sound system of risk management and internal controls in place enables the Trustee-Manager to achieve its strategic objectives, whilst safeguarding the business and assets of RHT. An effective risk management system allows both management and the Board to remain updated on the key risks and challenges faced by RHT. It also serves to guide the Trustee- Manager in decision making and effective allocation of resources.
In view of the above goal of having a sound system of risk management and internal controls, the Trustee-Manager has established an Internal Risk Committee (“IRC”) comprising of senior management, to undertake the role of managing the system of risk management and internal controls. Under the Trustee-Manager’s risk management system, the IRC is responsible for the identification of risks. Key risks are rated and the controls for mitigating the risks are evaluated. A risk register is maintained to track the rating of each key risk after the implementation of controls. Each IRC member is responsible for risks in their respective areas such as finance, operations, compliance, investments and information technology.
The IRC meets every quarter, or as and when required, to evaluate how the risks faced by RHT might have evolved following changes in both the operating environment and internal operations of RHT. Key risk indicators are used as a means for early identification of escalating risks or indications of changes in areas that affect RHT. The key risk indicators assists management and the Board in pre-empting issues that may be developing (whether internally or externally) and which may potentially have an adverse impact on RHT. Key risk indicators also provide management and the Board with information to consider when executing strategies for RHT.
The IRC also debates on whether new processes need to be implemented or existing processes revised in order to manage any new risks. During some of the IRC meetings, relevant staff might be invited to join the meetings or discussions in order to brief the IRC of changes that might have occurred in their respective areas, and to give their views on how these new risks might have arisen. The involvement of various staff within RHT in risk management discussions help to promote a culture where risk awareness and governance is integral to the daily operations of RHT.
The IRC also meet with the internal auditors, to compare each other’s assessment of the key risks and the adequacy of the internal controls. This helps to make sure that all gaps are filled wherever possible and no key risk is inadvertently left out. RHT also conducts half yearly Control Self-assessment (“CSA”) exercises to increase staff awareness within RHT in relation to key policies and processes, as well as to allow themselves to undertake a check on whether they have been complying with these policies and processes.
The discussions of the quarterly IRC are put up to the ARMC at each quarter’s meeting, where the ARMC will assess the effectiveness and adequacy of the system of risk management and internal controls within RHT TM. This is complemented by a quarterly report provided by the internal auditor to the ARMC on their findings, together with a quarterly report from management on the steps taken to address issues which were previously highlighted by the internal auditors. Apart from the quarterly reports by the internal auditor, the internal auditor also provides the ARMC with an annual review of the adequacy and effectiveness of RHT’s internal controls, including financial, operational, compliance and information technology controls. The internal auditor will also highlight areas of enhancements, if any, to the ARMC.
Both the ARMC and the Board also receive a quarterly letter of assurance from the CEO and CFO in relation to the respective quarter and/or full year results (whichever is applicable). The letter provides assurance in terms of the proper maintenance of the financial records of RHT, that the financial statements give a true and fair view of RHT’s operations and finances, and the effectiveness of RHT’s risk management and internal control systems.
After assessing the internal risk management framework that is in place, the quarterly reports from the IRC and internal auditor, as well as the annual assessment undertaken by both the internal auditor and external auditor, the ARMC and Board are in a position to comment on the adequacy of the internal controls of RHT.
For FY2018, based on the ARMC’s review of the internal risk management framework and internal controls which the management of RHT TM has implemented, the creation of an IRC to continuously monitor the risks affecting RHT and evaluate the efficacy of internal processes, as well as the reports from the internal auditor and external auditor, the Board with the concurrence of the ARMC, is of the opinion, that RHT has in place reasonable, adequate and effective risk management and internal controls including financial, operational, compliance and information technology controls.
However, the Board notes that the risk management framework put in place by the Trustee-Manager does not provide absolute assurance that RHT will not be affected by any unforeseen events as well as poor judgements in decision making, human errors, fraud and other irregularities.
There were material contracts between RHT Group and Fortis Healthcare Limited (“FHL”) as at the end of FY2018. Most of these contracts were entered into at the time of the listing of RHT on the SGX-ST. These material contracts are summarised within the section “Exempted Agreements” in the RHT Initial Public Offering (“IPO”) prospectus which can be found on RHT’s website, www.rhealthtrust.com. These exempted agreements were deemed to have been specifically approved by Unitholders upon their subscription for the units of RHT at the time of the IPO of RHT. There was another Hospital and Medical Services Agreement entered into in FY2015, between RHT Group and FHL, during the acquisition of the Mohali Clinical Establishment.
Principle 14: Companies should treat all shareholders fairly and equitably, and should recognise, protect and facilitate the exercise of shareholders’ rights and continually review and update such governance arrangements.
Principle 15: Companies should actively engage their shareholders and put in place an investor relations policy to promote regular, effective and fair communication with shareholders.
Principle 16: Companies should encourage greater shareholder participation at general meetings of shareholders, and allow shareholders the opportunity to communicate their views on various matters affecting the company.
RHT has in place an Investor Relations Policy which aims to provide current and potential Unitholders with accurate and timely information in accordance with best practices and rules, so as to enable them to make well-informed investment decisions. The Investor Relations Policy has been approved by the Board and is published on RHT’s website.
The Trustee-Manager ensures that material information is disseminated to Unitholders on an accurate and timely basis, with full and complete information to enable Unitholders to make form their investment decisions. Our announcements are disseminated via the SGXNET and the RHT website. Where necessary, the announcements may also be placed in the local newspapers. There is no selective disclosure of information.
The Trustee-Manager holds analyst briefings as well as investor conference calls every quarter after the release of financial results, or when there are announcements on material corporate actions. The analyst briefings facilitate research coverage on RHT through independent analysis from the analysts. The investor calls provide investors with a great opportunity for to hear from management and to have their queries answered.
Management participates actively in investor conferences which are held in different locations throughout the year, and embark on dedicated non-deal roadshows. Reaching out to investors through such platforms enables management to obtain direct feedback from investors or analysts. The Board is in turn briefed each quarter by management on the investor conferences and investor meetings which were held, in order for them to understand the views of our investors.
Whenever a Unitholders’ meeting is to be held, the notice of meeting will be disseminated to each Unitholder together with the circular and/or report, as well as published in the local newspapers and via SGXNET. Unitholders who are unable to attend the meeting are allowed to appoint up to two proxies to vote on his behalf at the meeting. RHT TM is not implementing absentia voting methods as we are of the opinion that the current provision for proxy voting is sufficient. Where there are separate issues to be put forth for Unitholders’ approval at the general meetings, such resolutions are separate and not bundled together, unless the resolutions are interdependent and form one significant proposal.
We held one AGM in FY2018, where all Board of Directors were present. The external auditors were also present at the AGM to address Unitholders’ queries regarding the conduct of audit, preparation and content of the auditors’ report. Our Company Secretary prepared the minutes of the AGM, which included relevant comments or questions from Unitholders, and the minutes are available for Unitholders upon request. Voting during the AGM was conducted by way of an electronic poll in order to promote greater transparency and allow exact and definitive results at the general meeting. Unitholders are briefed on rules of the AGM by the Chairman and are informed of the voting procedures by the electronic polling vendor. Unitholders are also given an opportunity to put forth any queries they may have before each resolution is put to vote. The detailed results of the AGM, which included the number of votes cast for and against each resolution, were disclosed via the SGXNET.
It is RHT TM’s internal policy that (i) an officer of the Trustee-Manager should not deal in RHT’s units on short term considerations; and (ii) the Trustee-Manager and its officers should not deal in RHT’s units during the period commencing two weeks before the announcement of RHT’s quarterly financial results, and one month commencing before the announcement of RHT’s fourth quarter and full year results. Reminders are sent to the Board of Directors as well as the staff of RHT TM when such blackout periods for trading in RHT’s units commence.
At any point in time, when any of the Directors or officers are in possession of confidential and price sensitive information, they are also reminded not to trade in the units of RHT, and to be mindful of the laws relating to insider trading at all times.
RHT TM, as Trustee-Manager of RHT, and the Board of Directors are responsible for safeguarding the interests of the Unitholders of RHT as a whole and managing the business of RHT. RHT TM is also required to act in the best interests of all the Unitholders of RHT as a whole, and give priority to the interests of all Unitholders of RHT over its own interests in the event of a conflict between the interests of all Unitholders as a whole and its own interests. The Trustee-Manager has implemented policies and practices in the management and governance of RHT, in order to ensure that RHT is managed in the interests of its Unitholders. The policies and practices include ensuring that:
4 Up till February 2018. Subsequent to February 2018, the Promoters are no longer the controlling shareholder of FHL, and in turn, RHT TM.
Under the revised Code of Collective Investment Scheme (the “CIS Code”) issued by the Monetary Authority of Singapore (“MAS”) which took effect on 1 January 2016, where fees are payable out of the deposited property of a property fund, the methodology and justifications for each type of fees payable should be disclosed. While RHT is constituted as a Business Trust and is not required to comply with the CIS Code, management has elected to disclose the fee computation methodology in this CG report for greater transparency. All the fees below are payable to the Trustee-Manager in the form of cash and/or Units (as the Trustee-Manager may elect) at the prevailing market price.
|Fee Payable by RHT||Rationale for Fee|
|(1) Base Fee
The base fee ("Base Fee") is 0.4% per annum of the value of the Trust Property5 , and paid quarterly in arrears.
|The Trustee-Manager receives a Management Fee
(comprising of the Base Fee and Performance Fee) from
RHT for managing all aspects of RHT, including but not
limited to, managing and enhancing the assets, financing
needs, investor relations and ensuring regulatory
| Performance Fee
The performance fee (“Performance Fee”) is 4.5% of the
Distributable Income of RHT (as defined in the Trust
Deed) 6, and paid quarterly in arrears.
The Base Fee and Performance Fee are payable to the
Trustee-Manager in the form of cash and/or Units
(as the Trustee-Manager may elect) at the prevailing
|The Base Fee increases in line with any increase in value
of RHT’s assets, reflecting the increase in work load and
scope with a greater volume of assets being managed.
In addition, it serves to incentivise the Trustee-Manager
to increase the value of the assets through asset
enhancement initiatives or other means.
The Performance Fee is pegged to the amount of
Distributable Income generated at RHT for Unitholders.
The ability of RHT TM to generate higher revenue
and manage expenses for RHT, the higher the
Distributable Income available for Unitholders of RHT.
This has the effect of directly aligning the interests
of the Trustee-Manager with that of the Unitholders
| (2) Trustee Fee
The trustee fee is 0.03% per annum of the value of the
Trust Property, subject to a minimum of S$15,000 per
month, and paid quarterly in arrears.
|As RHT TM performs the dual functions of both a
manager and a trustee for RHT, it also charges a trustee
fee. This trustee fee is pegged to the value of the assets
to reflect the increase in volume and scope of work with
an increase in asset value.
Any other substantial fee or charge (i.e. 0.1% or more of RHT’s asset value)
|No.||Fee Payable by RHT||Rationale for Fee|
|(3)|| Acquisition Fee
The acquisition fee (“Acquisition Fee”) will be:
Notwithstanding the above, in the event that any investment is held by the Religare Group as a nominee or in a fiduciary capacity or otherwise pursuant to any contractual obligation entered into in its ordinary course of business, the Acquisition Fee payable on the acquisition of such investment by RHT (if applicable) shall be 1.0% of the acquisition price of any investment acquired directly or indirectly by RHT (pro-rated if applicable to the proportion of RHT’s interest in the investment acquired).
No Acquisition Fee is payable to the Trustee-Manager in connection with the acquisition of the portfolio acquired at the time of the initial public offering (the “Initial Portfolio”), the acquisition of the Sponsor’s 51.0% interest in FHTL pursuant to the FHTL Call Option7 and the Compulsorily Convertible Preference Shares (“CCPS”) Subscription.
Any payment to third party agents or brokers in connection with the acquisition of any asset of RHT shall be paid by the Trustee-Manager to such persons out of the Trust Property of RHT, and not out of the Acquisition Fee received or to be received by the Trustee-Manager.
|In connection with the Performance Fee, the Acquisition Fee serves to encourage the Trustee-Manager to look for yield accretive quality assets to add to the portfolio of RHT. When undertaking an acquisition, a fair amount of time and expenses are incurred due to the lengthy process involved when carrying out due diligence and the number of external professionals involved. The Acquisition Fee also serves to compensate the Trustee-Manager for the additional time and expenses outside of that incurred for day to day operating expenses. The lower divestment fees payable to investments acquired from the Sponsor Group or promoter linked companies reflect the reduced effort required in sourcing for the acquisition.|
|(4)|| Divestment Fee
The divestment fee (“Divestment Fee”) will be 0.5% of the sale price of any investment sold, transferred or otherwise disposed of by RHT, whether directly or indirectly (prorated if applicable to the proportion of RHT’s interest in the investment sold, transferred or disposed).
No Divestment Fee is payable to the Trustee-Manager for the divestment by RHT to the Sponsor or its nominees of (i) the securities in FHTL pursuant to the FHTL Put Option8 and the put option in favour of Fortis Global Healthcare Infrastructure Pte. Ltd. (“FGHIPL”) in the FHTL Compulsorily Convertible Debentures (“CCD”) Subscription Agreement, and (ii) the CCPS pursuant to the put option in favour of Kanishka Healthcare Limited (“KHL”) in the CCPS Subscription.
Any payment to third party agents or brokers in connection with the divestment of any asset of RHT shall be paid by the Trustee-Manager to such persons out of the Trust Property of RHT, and not out of the Divestment Fee received or to be received by the Trustee-Manager.
Accordingly, there was no Divestment Fee paid to RHT TM when the 51.0% economic interest in FHTL was disposed of in October 2016.
The development fee (“Development Fee”) will be 2.0% of the total project costs9 for undertaking (directly or indirectly) a Development Project on behalf of RHT incurred (pro-rated if applicable to the interest of RHT in the Development Project).
“Development Project” means a project involving the development or redevelopment of medical and healthcare assets which are acquired or held by RHT. For the avoidance of doubt, this includes any redevelopment undertaken on the Initial Portfolio.
|A Development Project involves the construction of new assets which is frequently carried out over a few years. Developing a project requires a dedicated project team to be assigned to oversee the project and often includes the appointment of specialised external project managers as well. The Development Fee compensates the Trustee- Manager for maintaining a separate team of personnel and the expenses related to the project over the years.|
Asset Management Fee
The asset management fee (“Asset Management Fee”) will be 1.0% of the total Gross Revenue10 for asset management services provided in respect of assets in the Trust Property, and paid quarterly in arrears.
No Asset Management Fee will be payable in respect of assets operated by the Sponsor Group. For the avoidance of doubt, no Asset Management Fee is payable to the Trustee-Manager in respect of the Initial Portfolio and the CCPS in Escorts Heart Institute & Research Centre Limited (“EHIRCL”) held pursuant to the CCPS Subscription.
In managing RHT’s assets, RHT TM incurs expenses, including but not limited to, ensuring the smooth running of assets for the operators, compliance with regulations and negotiations with vendors. This Asset Management Fee will reimburse the Trustee-Manager for such expenses incurred.
Linking the Asset Management Fee of the Trustee- Manager to that of the gross revenue of the operator aligns the interests of the Trustee-Manager with that of the Unitholders of RHT. As a portion of RHT’s revenue is pegged to the gross revenue of the operator, a higher revenue generated by the operator results in higher revenue for RHT. This also benefits the Unitholders of RHT as the Trustee-Manager is incentivised to manage the assets in a way that generates more revenue for the operator.
|No.||Fee Payable by RHT||Rationale for Fee|
Marketing Services Fee
If a third party agent secures a lease (outside India) and/or service contract with any person (other than a member of the Sponsor Group) for a particular medical and healthcare asset (or part thereof) on behalf of RHT, the Trustee- Manager will be responsible for all Marketing Services Fee payable to such third party agent, and the Trustee- Manager will be entitled to a Marketing Services Fee of:
For the avoidance of doubt, the Marketing Services Fee includes all commission and fees payable to third party agents.
The Marketing Services Fee may be adjusted accordingly at the time of securing or renewal of a lease and/or service contract by the Trustee-Manager or a third party agent, to be consistent with and no higher than the prevailing market rates of such Marketing Services Fee in the country where the asset is located.
|The Marketing Services Fee is structured to incentivise the Trustee-Manager to secure leases for RHT’s assets with longer lease terms and which command a higher revenue. There is also a higher Marketing Services Fee payable when it involves a new tenant due to the extra work involved in sourcing and attracting new operators for RHT’s assets.|
|Board of Directors||Appointed|
|Mr Vivek Mehra, Non-executive Chairman||1 October 2017|
|Mr Ravi Mehrotra, Executive Chairman||Resigned on 30 September 2017|
|Mr Gurpreet Singh Dhillon, Executive Director & CEO||22 July 20111|
|Mr Pawanpreet Singh, Executive Director & CFO||1 July 20133|
|Mr Eng Meng Leong, Independent Director||1 July 20133|
|Mr Sydney Michael Hwang, Independent Director||7 September 20122|
|Dr Yogendra Nath Mathur, Lead Independent Director||7 September 20122|
|Mr Peter Joseph Seymour Rowe, Independent Director||7 September 20122|
|1reappointed on 28 July 2014
2reappointed on 6 August 2015
3reappointed on 29 July 2016.
|Board Committees & Members|
|Audit & Risk Management Committee||Nominating Committee||Remuneration Committee|
|1. Mr Peter Joseph Seymour Rowe, Chairman||1. Mr Sydney Michael Hwang, Chairman||1. Mr Eng Meng Leong, Chairman|
|2. Mr Eng Meng Leong||2. Mr Vivek Mehra(1)||2. Mr Sydney Michael Hwang|
|3. Dr Yogendra Nath Mathur||3. Dr Yogendra Nath Mathur||3. Mr Peter Joseph Seymour Rowe|
|4. Mr Ravi Mehrotra(2)
(1) Mr Vivek Mehra was appointed Independent Director, Non-executive Chairman of the Board and member of the NC on 1 October 2017.
(2) Mr Ravi Mehrotra resigned as Executive Director on 30 September 2017 and ceased to be the Executive Chairman of the Board and member of the NC on the same day.
The main objective of the ARMC shall be to assist the Board in fulfilling its responsibilities as the Board of the Trustee-Manager of RHT. To achieve this goal, the ARMC shall:
Roles and Function
The duties and functions of the ARMC shall include the following:
Risk Management and Internal Controls
Internal & External Audit Processes
Interested Person Transactions and Conflicts of Interest
Other areas of responsibility of the ARMC include:
The main objective of the NC shall be to make recommendations to the Board on all Board appointments. The NC shall decide how the Board’s performance is to be evaluated and develop objective performance criteria which address how the Board has enhanced long-term Unitholders’ value. It shall also implement a process for assessing the effectiveness of the Board as a whole and for assessing the contribution of each individual Director to the effectiveness of the Board. The Chairman will review the results of the performance evaluation of the Board, and where appropriate, propose new members to be appointed to the Board of Directors or seek the resignation of Directors, in consultation with the NC.
Roles and Function
The duties and functions of the NC shall include the following:
The primary objective of the RC is to recommend to the Board a framework and specific remuneration package for the Directors and the CEO of RHT TM.
With regard to remuneration, the RC will review the framework of remuneration and the specific remuneration packages for the Directors and the key executive officers of the Trustee-Manager. The RC shall cover all aspects of remuneration, including but not limited to, Directors’ fees, salaries, allowances, bonuses, options and benefits-in-kind.
Roles and Functions
And other major appointments over the last 3 years
|Name of Director||Current Directorships and other major appointments||Past appointments over the last 3 years|
(1)Treasurer of The Asthma, Bronchitis & Cancer
Lung Foundation of India
|Gurpreet Singh Dhillon||
|Eng Meng Leong||
|Sydney Michael Hwang||
|Dr Yogendra Nath Mathur||
(1) Member of Maharaj Jagat Singh Medical
|Peter Joseph Seymour Rowe||
(1) Chairman of the Managed Investments
Scheme Compliance Committees